Skip to main content
. Author manuscript; available in PMC: 2024 Jan 21.
Published in final edited form as: Mol Pharm. 2023 Feb 1;20(3):1670–1680. doi: 10.1021/acs.molpharmaceut.2c00880

Figure 4.

Figure 4.

(A) Postinjection time point radiant efficiencies of tumor region of osteosarcoma tumor-bearing NSG mice after tail vein injection of Cy5.5-labeled HPMA–CHP, HPMA–SCHP, or CHP; (B) AUC and t1/2 of compounds at the tumor, calculated using noncompartmental pharmacokinetic analysis; and (C) radiant efficiencies at postinjection time points with corresponding comparative p values (mean ± SD, N = 6, *p < 0.05, **p < 0.01, and ***p < 0.001).